{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:30:47Z","timestamp":1785742247663,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","award":["R367-A25341-B15690"],"award-info":[{"award-number":["R367-A25341-B15690"]}],"id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008241","name":"Desir\u00e9e og Niels Ydes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.msard.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T21:51:44Z","timestamp":1527889904000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Real-life persistence and tolerability with dimethyl fumarate"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-2188","authenticated-orcid":false,"given":"Tobias","family":"Sejbaek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Nybo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.05.007_bib0001","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1212\/NXI.0000000000000274","article-title":"Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate","volume":"3","author":"Baharnoori","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.05.007_bib0002","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.007_bib0003","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","author":"Gold","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.007_bib0004","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.05.007_bib0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2147\/PPA.S108121","article-title":"Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines","volume":"10","author":"Jongen","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2018.05.007_bib0006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458513507818","article-title":"Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study","volume":"20","author":"Kita","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.007_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/00365510500208332","article-title":"Pre-analytical factors and measurement uncertainty","volume":"65","author":"Kouri","year":"2005","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.msard.2018.05.007_bib0008","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","article-title":"PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter","volume":"87","author":"Lehmann-Horn","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.05.007_bib0009","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/1352458514559299","article-title":"Dimethyl fumarate associated lymphopenia in clinical practice","volume":"21","author":"Longbrake","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.007_bib0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/14737175.2014.945523","article-title":"Fostering adherence to injectable disease-modifying therapies in multiple sclerosis","volume":"14","author":"Lugaresi","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2018.05.007_bib0011","first-page":"S24","article-title":"Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.msard.2018.05.007_bib0012","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.msard.2014.03.003","article-title":"Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel","volume":"3","author":"Phillips","year":"2014","journal-title":"Multiple Sclerosis Relat. Disord."},{"key":"10.1016\/j.msard.2018.05.007_bib0013","series-title":"The Danish Council for the Use of Expensive Hospital Medicines","year":"2016"},{"key":"10.1016\/j.msard.2018.05.007_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/00365519950185229","article-title":"Current databases on biological variation: pros, cons and progress","volume":"59","author":"Ricos","year":"1999","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.msard.2018.05.007_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.msard.2018.05.007_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2018.05.007_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40120-015-0037-x","article-title":"Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a delphi study","volume":"4","author":"Theodore Phillips","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2018.05.007_bib0018","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","article-title":"The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis","volume":"19","author":"Thomas","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.msard.2018.05.007_bib0019","article-title":"Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose","author":"Vermersch","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.05.007_bib0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1756285616661929","article-title":"Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis","volume":"9","author":"Zhovtis Ryerson","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:17Z","timestamp":1761900197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":20,"alternative-id":["S2211034818301470"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.007","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life persistence and tolerability with dimethyl fumarate","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}